.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
McKinsey
Accenture
US Department of Justice
Citi
QuintilesIMS
Argus Health
US Army
Mallinckrodt
Johnson and Johnson

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Treatment of diabetes mellitus
Abstract:The present invention relates to methods of preparing a product or a composition containing amylin or amylin with insulin for treating diabetes mellitus.
Inventor(s): Cooper; Garth J. S. (Woodstock, GB2)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Nov 17, 1994
Application Number:08/341,342
Claims:1. A method of preparing a product for treatment of a patient suffering from diabetes mellitus which comprises bringing a predetermined amount of an amylin agonist into the form of a composition suitable for parenteral administration to said diabetic patient.

2. The method of claim 1 wherein said amylin agonist is amylin.

3. The method of claim 1 wherein said amylin agonist is a conservative variant of amylin.

4. The method of claim 2 wherein said amylin is human amylin.

5. The method of claim 1 wherein said amylin agonist is CGRP.

6. The method of claim 1 wherein said amylin agonist is a conservative variant of CGRP.

7. The method of claim 5 wherein said CGRP is human CGRP.

8. The method of claim 1 wherein said parenteral administration is subcutaneous.

9. A method of preparing a composition for treatment of a patient suffering from diabetes mellitus which comprises bringing a predetermined amount of an insulin and a predetermined amount of an amylin agonist into the form of a composition suitable for parenteral administration to said diabetic patient.

10. The method of claim 9 wherein said amylin agonist is amylin.

11. The method of claim 9 wherein said amylin agonist is a conservative variant of amylin.

12. The method of claim 10 wherein said amylin is human amylin.

13. The method of claim 9 wherein said amylin agonist is CGRP.

14. The method of claim 9 wherein said amylin agonist is a conservative variant of CGRP.

15. The method of claim 13 wherein said CGRP is human CGRP.

16. The method of claim 9 wherein said insulin and said amylin agonist are in a ratio of from 100:1 to 0.1:1.

17. The method of claim 9 wherein said parenteral administration is subcutaneous.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Chubb
UBS
Medtronic
Baxter
McKesson
Daiichi Sankyo
Harvard Business School
Cipla
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot